)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Humacyte (HUMA) investor relations material
Humacyte Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary11 Aug, 2025
Executive summary
Achieved first commercial sales of FDA-approved Symvess in Q2 2025, marking transition to a commercial-stage company and expanding hospital eligibility from 5 to over 200 facilities, including military and civilian sites.
Secured ECAT listing from the US Defense Logistics Agency, enabling access to 35 military and 160 VA hospitals, with initial and repeat sales to military facilities.
Positive topline results from V007 Phase III trial in AV access for hemodialysis, with data presented at major conferences and accepted for publication.
Implemented cost reduction actions in April 2025, including a 30-employee workforce reduction and deferred hiring to extend cash runway.
Overcame headwinds from public attacks and challenging economic environment, with commercial momentum accelerating in June and July.
Financial highlights
Q2 2025 revenue was $0.3M ($0.1M US sales, $0.2M research collaboration); $0.8M for six months ended 06/30/2025.
Net loss for Q2 2025 was $37.7M, improved from $56.7M prior year; net income of $1.5M for six months, versus $88.6M loss prior year, driven by non-cash remeasurement of contingent earn-out liability.
R&D expenses: $22M for Q2 2025 (down from $23.8M prior year); $37.4M for six months (down from $45M prior year).
SG&A expenses: $7.8M for Q2 2025 (up from $5.7M prior year); $15.9M for six months (up from $11.1M prior year), reflecting commercial launch costs.
Cash, cash equivalents, and restricted cash totaled $88.4M as of 06/30/2025; $46.7M raised in March 2025 public offering.
Outlook and guidance
Expect continued growth in hospital eligibility and sales, with a focus on high-volume centers and further military facility penetration.
Plan to complete VO12 trial enrollment (~150 patients) by year-end 2025, with interim analysis in April 2026 and potential BLA filing in 2026.
Anticipate IND filing for coronary artery bypass graft program in late 2025, with clinical trial start in 2026.
Management believes available cash and equity facilities will fund operations for at least 12 months; additional capital may be required for long-term operations.
Cost reduction actions expected to yield over $50M in savings across 2025–2026.
How does ECAT approval affect VAC needs?
Assess impact of price cut on VAC approvals.
Update on CABG program and IND filing.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Humacyte earnings date
Q3 20257 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Humacyte Inc. is a clinical-stage biotechnology company developing regenerative medicine products. It focuses on bioengineered human tissues and organs for vascular and other applications. The company’s technology platform is designed to produce off-the-shelf, universally implantable tissues. The company is headquartered in Durham, North Carolina, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage